Status epilepticus in children. Clinical lecture
V.M. Frolova, A.S. Kotov, K.V. Firsov
Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky
Status epilepticus (SE) is characterized by prolonged or repeated seizures\episodes without returning to the normal patient state. Seizure/episode can last at least 30 minutes, otherwise, there can be several seizures without restoring functions between them for more than
30 minutes. The highest SE frequency is in the neonatal period, then it decreases for about five years. In persons aged 5 to 40 years, SE episodes are relatively rare. SE requires emergency treatment and diagnostic measures aimed at stabilizing vital functions, root cause diagnosis and early determination of a treatment tactics for both clinical and electroencephalogram (EEG) episode manifestations. The SE therapy first-line drugs are benzodiazepines. Many patients need further prescription with fentanyl, valproic acid, phenobarbital or levetiracetam.
If benzodiazepines and additional drugs administration do not let interrupting the episod e, the patient is diagnosed with refractory SE. In this case, it is necessary to put the patient into the medically induced coma in order to interrupt SE. The period in a coma makes it possible to add additional drugs and determine the episode causes, requiring special treatment.
Keywords: epilepsy, epileptic, status, children, emergency intervention, urgent intervention, refractory, medically induced coma.
For citation: Frolova V.M., Kotov A.S., Firsov K.V. Status epilepticus in children. Clinical lecture. RMJ. Medical Review. 2019;5:37–40.
2. Roger J., Lob H., Tassinari C.A. Status epilepticus. In Handbook of Clinical Neurology: The Epilepsies; Magnus, O., de Lorentz Haas, A.M., Eds.; North Holland Publishing Company: Amsterdam, The Netherlands. 1974;15:145–188.
3. Commission on epidemiology and prognosis, international league against epilepsy: Guidelines for epidemiologic studies on epilepsy. Epilepsia. 1993;34:592–596.
4. Alford E.L., Wheless J.W., Phelps S.J. Treatment of generalized convulsive status epilepticus in pediatric patients. J. Pediatr. Pharmacol. Ther. 2015;20:260–289.
5. Chin R.F., Neville B.G., Peckham C. et al. Treatment of community-onset, childhood convulsive status epilepticus: A prospective, population-based study. Lancet Neurol. 2008;7:696–703.
6. Котов А.С. Генерализованный судорожный эпилептический статус. РМЖ. 2015;12: 651–655. [Kotov A.S. Generalized convulsive epileptic status. RMJ. 2015;12:651–655 (in Russ.)].
7. Dham B.S., Hunter K., Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit. Care. 2014;20:476–483.
8. DeLorenzo R.J., Hauser W.A., Towne A.R. et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46: 1029–1035.
9. Herman S.T., Abend N.S., Bleck T.P. et al. Consensus statement on continuous EEG in critically ill adults and children, part I: Indications. J. Clin. Neurophysiol. 2015;32:87–95.
10. Riviello J.J., Ashwal S., Hirtz D. et al. Practice parameter: Diagnostic assessment of the child with status epilepticus (an evidence-based review). Neurology. 2006;67:1542–1550.
11. Beckham J.D., Tyler K.L., IDSA. Initial management of acute bacterial meningitis in adults: Summary of IDSA guidelines. Rev. Neurol. Dis. 2006;3:57–60.
12. Davis R., Dalmau J. Autoimmunity, seizures, and status epilepticus. Epilepsia. 2013;54(Suppl. 6):46–49.
13. Glauser T., Shinnar S., Gloss D. et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016:16;48–61.
14. Babl F.E., Sheriff N., Borland M. et al. Emergency management of paediatric status epilepticus in Australia and New Zealand: Practice patterns in the context of clinical practice guidelines. J. Paediatr. Child Health. 2009;45:541–546.
15. Reiter P.D., Huff A.D., Knupp K.G., Valuck R.J. Intravenous levetiracetam in the management of acute seizures in children. Pediatr. Neurol. 2010;43:117–121.
16. Brevoord J.C., Joosten K.F., Arts W.F. et al. Status epilepticus: Clinical analysisof a treatment protocol based on midazolam and phenytoin. J. Child Neurol. 2005:20;476–481.
17. Holtkamp M., Othman J., Buchheim K. et al. A «malignant» variant of status epilepticus. Arch. Neurol. 2005;62:1428–1431.
18. Shorvon S., Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–2818.
19. Van Lierde I., van Paesschen W., Dupont P. et al. De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: A review of six cases. Acta Neurol. Belg. 2003;103:88–94.
20. Wilder-Smith E.P., Lim E.C., Teoh H.L. et al. The NORSE (new-onset refractory status epilepticus) syndrome: Defining a disease entity. Ann. Acad. Med. Singap. 2005;34:417–420.
21. Kramer U., Chi C.S., Lin K.L. et al. Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome: A multicenter study on 77 children. Epilepsia. 2011;52:1956–1965.
22. Riviello, J.J. Jr., Claassen J., LaRoche S.M. et al. Treatment of status epilepticus: An international survey of experts. Neurocrit. Care. 2013;18:193–200.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
